Form D · Biotechnology
OncoVerity, Inc.
Aurora, CO · CIK 0001943593
Offering snapshot reported Dec 10, 2024 · SEC filing
- Reported sold
- $14M Offering amount: $42M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 25, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 10, 2024 | Initial | $14,000,000 | No comparison | 2 | SEC filing |
| Aug 22, 2022 | Initial | $4,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-531662
Source: Form D, filed Dec 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Massimiliano Colao | Director, Executive |
| Steven Hess | Director |
| Arjen Lemmen | Director |
| Kimberly Muller | Director |
| Clayton Smith | Executive |
| Steven Van Nurden | Director, Executive |
| Petra Van Vlierberghe | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
12635 E Montview Blvd.
Aurora, CO, 80045
Aurora, CO, 80045